[GSK] GSK: Q3 2026 earnings preview, can core profit grow as Nuvalent consolidates?

GSK is a UK-based biopharma group that prevents and treats disease with three product groups: specialty medicines, vaccines and general medicines[1]. The earnings calendar lists 2026-10-28 for the GSK Q3 2026 earnings release, covering the third quarter of 2026, ending September 30, 2026[2]. In the second quarter of 2026, turnover was £8.41 billion, up 5% at constant exchange rates (CER); core operating profit was £2.80 billion, up 7%, for a core operating margin of 33.3%; and core earnings per share were 50.5 pence, up 9%[3]. HIV sales rose 10% to £2.08 billion, while general medicines fell 9% to £2.34 billion[4]. On July 28 GSK reaffirmed its full-year 2026 guidance at CER: turnover growth of 3%-5% in the upper half of the range, core operating profit growth of 7%-9% in the upper half, and core EPS growth of 7%-9% in the lower half[5]. Management also said full-year profit growth would be significantly weighted to the fourth quarter, with the third quarter absorbing the Nuvalent consolidation and acquisition-related interest[6]. Five analysts tracked by Drillr expect average third-quarter turnover of £9.02 billion (range £8.94 billion to £9.12 billion), and 15 analysts expect average full-year 2026 turnover of £34.39 billion[7].

Three things matter most in these results. First, can HIV keep growing at close to 10%? Long-acting injectables Cabenuva and Apretude delivered 80% of HIV growth in the second quarter[8], but working back from the full-year "high single-digit" guidance, HIV needs only about 4% to 8% growth in the second half, so the guidance already allows for a slowdown[6]. Second, can core operating profit still grow in the third quarter? Respiratory, immunology and inflammation (RI&I) grew 19% and oncology 17% in the second quarter[4], but core R&D rose 13%, faster than turnover[9], and the third quarter is the first to include Nuvalent, acquired on July 15[10]; this decides whether launch growth can cover the investment. Third, will the general medicines decline narrow in the second half as management says? US general medicines fell 17% in the second quarter[11]; management attributed part of that to a high base from a one-off favorable pricing adjustment a year earlier and said it saw pressure easing in the second half[12]. If general medicines still fall more than 6% in the third quarter, support for the full-year turnover guidance weakens.

Company Background and Business Structure

GSK reports two segments, Commercial Operations and Total R&D; all sales sit in Commercial Operations, which is split into specialty medicines, vaccines and general medicines[1]. Its research spending is concentrated in four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases[1]. The HIV business is run by ViiV Healthcare, which GSK majority-owns, with Pfizer and Shionogi as shareholders[13]. The contingent consideration created when ViiV bought out Shionogi's former joint-venture interest is paid in cash as HIV sales accrue, and the present value of the amount owed to Shionogi was £5.43 billion at the end of 2025[14]. In 2026 GSK completed the acquisitions of RAPT and 35Pharma[15], closed the Nuvalent acquisition on July 15[10], and launched a three-year Accelerate Growth programme targeting £1.9 billion of annual cost savings by 2029 at a one-time cost of £2.4 billion[16].

Specialty medicines are already GSK's largest product group, and their share is still rising. Of 2025 turnover of £32.67 billion, specialty medicines contributed £13.47 billion (about 41%), including HIV at £7.69 billion and oncology at £1.98 billion; vaccines contributed £9.16 billion (about 28%), including the shingles vaccine Shingrix at £3.56 billion; and general medicines contributed £10.04 billion (about 31%), including respiratory products at £7.07 billion[17]. In the first half of 2026, specialty medicines were about 44% of turnover, vaccines about 28% and general medicines about 29%, and the US contributed £8.05 billion, roughly half of the £16.04 billion total[4].

GSK's US revenue depends heavily on a few wholesalers and passes through complex rebate settlements. In 2025 its three US wholesalers bought £5.35 billion, £4.80 billion and £3.21 billion respectively, after which GSK pays rebates and discounts through Medicaid, Ryan White, Medicare Part D, managed care and other channels; the US returns and rebates accrual stood at £4.89 billion at the end of 2025[18]. Vaccine sales are shaped by government immunization programs, public tenders and US CDC stockpile purchases[11][19]. On the manufacturing side, more than 24,000 people work across GSK's 33 sites, which supplied 1.64 billion packs of medicines and 389 million vaccine doses in 2025[20], with general medicines accounting for more than 70% of total supply volume[21].

Financial History and Current Position

GSK delivered solid growth in 2025, driven mainly by specialty medicines. Turnover was £32.67 billion, up 4% at actual exchange rates (AER) and 7% at CER; specialty medicines grew 17% at CER, vaccines grew 2% and general medicines fell 1%[22]. Reported operating profit was £7.93 billion, profit attributable to shareholders was £5.72 billion and basic EPS was 141.1 pence; cash generated from operations was £8.94 billion and net cash inflow from operating activities was £7.74 billion; net debt rose from £13.10 billion at the start of the year to £14.45 billion at year-end[23]. Core R&D spending was £6.57 billion, or 20.1% of sales[24], and full-year dividends totaled 66 pence, or £2.66 billion[25].

Core profit kept growing in the first two quarters of 2026, but large impairments depressed reported profit in the second quarter. First-quarter turnover was £7.63 billion, up 5% at CER, and core operating profit was £2.65 billion, up 10%, for a 34.7% core operating margin[26]. Second-quarter turnover was £8.41 billion, up 5%, and core operating profit was £2.80 billion, up 7%, for a 33.3% margin; impairments totaling £1.90 billion on camlipixant and the Alector collaboration assets[27] cut reported operating profit 76% to £481 million and reported EPS to 10.8 pence[3]. First-half turnover was £16.04 billion and core operating profit was £5.45 billion, up 5% and 8% at CER respectively[3].

Cash flow improved on last year, but the balance sheet took on clearly more leverage after the acquisitions. First-half 2026 free cash flow was £2.81 billion, up from £1.82 billion a year earlier[28]. Net debt was £15.13 billion at the end of June, up £679 million from the start of the year, mainly because of £2.08 billion of net acquisition costs for RAPT and 35Pharma, £1.37 billion of shareholder dividends and £634 million of share buybacks[15]. The Nuvalent deal cost about £7.1 billion net of cash acquired and was funded primarily from new and existing debt facilities[10]; management said net debt rose to about £22 billion after the deal, just under twice 2025 core EBITDA[29]. GSK declared a 17 pence second-quarter dividend and expects a full-year 2026 dividend of 70 pence[30].

Operating Model

GSK's turnover is the sum of specialty medicines, vaccines and general medicines, and each block has different drivers and lags. Long-acting HIV injectables generate revenue as patients on injections times injections per year times net price: patients move from daily oral Triumeq and Tivicay to Dovato or to Cabenuva and Apretude given every two months[13], and the products are sold through US wholesalers and recognized as revenue only after government and commercial rebates[18]. Growth in RI&I and oncology depends on new approvals, reimbursement and billing-code coverage; Exdensur's US J-code, for example, took effect on July 1, 2026[16]. Vaccine revenue is driven by inclusion in publicly funded programs and by public tenders, and tender deliveries and prior-period rebate adjustments can swing a single quarter[19]. General medicines are mainly inhaled products such as Trelegy, which in the US are hit at once by Medicare benefit design, channel mix pricing and generic competition[31].

Core operating profit equals turnover minus core cost of sales, SG&A and R&D, plus royalty income, and the mix shift toward specialty medicines and higher-margin vaccines is the main positive force on margin[9]. In the second quarter, core cost of sales was 22.6% of sales, lower because of more specialty and higher-margin vaccine sales; core SG&A was 26.1%, higher because of launch investment in Blenrep and Exdensur; core R&D was £1.72 billion, 20.5% of sales and up 13%; and royalty income fell 17% to £204 million because the prior-year quarter included historic royalties from an IP settlement[9]. Reported profit also deducts adjusting items such as intangible impairments and Shionogi contingent consideration remeasurements; second-quarter transaction-related adjustments were a net £491 million charge, of which £392 million reflected a higher Shionogi liability after sales forecasts were raised[27]. That is why reported profit swings far more than core profit.

Operating cash equals core profit plus depreciation and amortization and working-capital changes, minus contingent consideration paid through operating activities and tax; free cash flow further deducts capital expenditure, intangible purchases, interest and dividends to non-controlling interests[28]. Second-quarter cash generated from operations was £2.91 billion, including £348 million paid to Shionogi[32]; purchases of property, plant and equipment were £328 million and free cash flow was £1.99 billion[28]. First-half free cash flow of £2.81 billion covered £1.37 billion of dividends and £634 million of buybacks but not the acquisitions, so RAPT, 35Pharma and Nuvalent were funded mainly with debt[15][10]. On timing, faster R&D and acquisition interest hit expenses in the same quarter, and management said R&D investment would keep growing faster than sales[6], while new launches need reimbursement, billing codes and prescription build-up before they show up as sales in later quarters.

Industry and Competitive Position

GSK has leading products in HIV, adult vaccines and respiratory, but faces direct rivals in each. In HIV, ViiV has the long-acting treatment Cabenuva and the long-acting prevention drug Apretude, and its main rivals include Gilead's oral Biktarvy and long-acting prevention drug lenacapavir. On the second-quarter call, management acknowledged that multiple competitors are pursuing long-acting treatment and prevention, some of them ahead in development[29], and Apretude's growth comes from a competitive US long-acting prevention market[8]. In vaccines, Shingrix is launched in 61 countries, 29 of them with public funding, and markets outside the US made up 66% of its 2025 global sales[33]; the RSV vaccine Arexvy competes with Pfizer's and Moderna's products.

GSK's biggest structural challenge is the loss of exclusivity for its dolutegravir oral medicines, along with generic and US pricing pressure on general medicines. US patents on dolutegravir products such as Dovato, Triumeq and Tivicay expire in 2028 and EU patents in 2029, while long-acting cabotegravir is protected to 2031[34]; management added that the current every-two-months Cabenuva has further patent protection through 2040 and that a three-times-yearly formulation has protection pending through 2047[12]. GSK targets more than £40 billion of sales by 2031 and a stable to improving operating margin through the 2028-2030 loss-of-exclusivity period[30]. Respiratory and oncology are the main candidates to fill the gap, but oncology's Jemperli, Ojjaara, Zejula and Blenrep together brought in £569 million in the second quarter[4], still far smaller than HIV. GSK does not disclose HIV patient numbers, prescription volumes or unit prices, so the switching and pricing contributions of long-acting injectables can only be separated using the company's own commentary.

Core Debates

Long-acting injectables now drive about 80% of HIV growth. Can they keep HIV sales growing close to 10% in the third quarter?

HIV is GSK's largest single business, and whether it can hand growth to long-acting injectables before patents expire sets the company's revenue base after 2028. HIV sales were £7.69 billion in 2025, about 24% of turnover[17]. Dolutegravir's US patent expires in 2028 and its EU patent in 2029, while cabotegravir long-acting injectables are protected to 2031[34]. In July GSK raised its full-year HIV sales growth guidance from mid-to-high single digits to high single digits, mainly because Cabenuva beat expectations[6].

Second-quarter data show switching is still accelerating. HIV sales were £2.08 billion, up 10% at CER, and first-half sales of £3.90 billion were also up 10%[4]. Long-acting injectables totaled £593 million, up 34%, with Cabenuva at £453 million, up 33%, and Apretude at £140 million, up 39%; first-half long-acting sales reached £1.08 billion[35]. Long-acting injectables delivered 80% of HIV growth in the quarter and 35% of US HIV sales[8], up from 34% in the first quarter[36]. Dovato grew 14% to £749 million, while Triumeq fell 15% and Tivicay 5%[35].

The alternative reading is that part of the US growth came from pricing rather than patient demand, and once that pricing benefit fades the same switching pace would yield slower revenue growth. GSK's 2025 annual report said patient demand contributed about 10 percentage points of that year's HIV growth, with favorable pricing from US channel mix also helping[13], and its second-quarter commentary again cited the channel mix pricing benefit[8]. In financial terms, after patients switch, products are sold through wholesalers and recognized as HIV sales only after Medicaid, Ryan White, Medicare Part D and other rebates[18]. Higher HIV sales also raise the contingent consideration owed to Shionogi: GSK paid it £348 million in cash in the second quarter[32] and booked a £392 million remeasurement charge after raising sales forecasts[27].

What remains unresolved is whether long-acting injectables can sustain growth of around 30% on demand alone once the pricing benefit fades. Working back from the full-year guidance, second-half HIV growth needs only about 4% to 8%[6], so even a third-quarter slowdown would not necessarily break guidance. The third-quarter report should answer four questions: whether HIV growth at CER is at least 4%, whether long-acting growth holds near 30%, whether long-acting injectables keep gaining share of US HIV sales, and how Dovato growth compares with the declines in Triumeq and Tivicay. If third-quarter HIV growth falls below 4%, or long-acting growth drops below 20%, the view that switching is enough to sustain HIV growth would be falsified.

Specialty launches are still growing at double-digit rates, but faster R&D and the Nuvalent consolidation are raising costs. Can core operating profit still grow in the third quarter?

Whether specialty launches can outgrow the costs of faster R&D and acquisitions will directly set the direction of third-quarter core operating profit. GSK's growth plan relies on specialty medicines to replace products losing exclusivity, and management said R&D spending now exceeds £7 billion a year, up more than 50% since 2021, and would keep growing faster than sales[6]. In the second quarter RI&I grew 19% and oncology 17%[4], while core operating profit rose 7% at a 33.3% margin[3]. But management has flagged that full-year profit growth will be significantly fourth-quarter weighted, with the third quarter absorbing the Nuvalent consolidation and acquisition interest[6].

The supporting evidence is that launches are still ramping, which is why GSK moved its turnover and core operating profit guidance to the upper half of the range in July[5]. First-half RI&I grew 17% and oncology 22%[4]; Exdensur new patient starts increased in the second quarter in the US, Japan and Germany[8], and its US J-code took effect on July 1[16]; and Nuvalent's Jideytro (zidesamtinib) won FDA approval in July[10]. On the other side, 12 percentage points of Nucala's 23% second-quarter growth came from US channel mix pricing adjustments[8], and an estimate based on product mix puts RI&I's underlying growth at about 13% without them. In oncology, Zejula fell 33%, while the two new launches Exdensur and Blenrep together brought in only £54 million[35].

In financial terms, approvals, reimbursement and billing-code coverage first bring prescriptions and new patients, which then turn into higher-margin RI&I and oncology sales and lower the core cost-of-sales ratio[9]. But launch promotion also raises SG&A, and more than 20 phase III trials plus Nuvalent's programs push up core R&D: second-quarter core R&D was £1.72 billion, up 13%, versus 5% turnover growth[9], and GSK raised the number of phase III trials it plans to start in 2026 from more than 10 to more than 20[37]. Nuvalent's roughly £7.1 billion net cost was funded mainly with debt[10], and acquisition interest has already led GSK to move core EPS guidance to the lower half of the 7%-9% range[6].

What remains unresolved is how much Nuvalent will add to R&D costs, because GSK will disclose the provisional acquisition accounting for the first time in its third-quarter results[10]; the FDA decision date for neladalkib is November 27, 2026[16]. The third-quarter report should show whether core operating profit grows at CER, whether RI&I growth stays in double digits excluding one-off pricing, how fast oncology grows excluding Nuvalent, and how fast core R&D grows and what share of sales it takes. If third-quarter core operating profit falls at CER, or RI&I growth drops below 10%, the view that launch growth can cover the investment would not hold.

Shingrix is growing about 20% in Europe on expanded public funding. Can that offset slowing US uptake and keep vaccine sales flat for the year?

Vaccines make up about 28% of GSK's turnover and carry higher margins than general medicines, so whether they hold flat for the year decides whether the mix improvement can continue. Vaccine sales were £9.16 billion in 2025, including £3.56 billion from Shingrix[17]; Shingrix US sales fell 20% in 2025, and markets outside the US rose to 66% of its sales[33]. GSK's 2026 planning assumption for vaccines is only broadly stable to low single-digit growth[5], and after 6% first-half growth, that allows second-half sales to fall by as much as about 5%[4].

European demand is the strongest support today, but second-quarter growth included one-off factors. Shingrix sales in Europe rose 21% to £434 million in the second quarter and 38% in the first half[38], driven by demand in the Nordics and Austria[11]; meningitis vaccines grew 21%[4]; and the US cumulative Shingrix immunization rate reached 45%[19]. On the other hand, 3 percentage points of the 8% second-quarter vaccine growth came from prior-period rebate adjustments, and Arexvy's surge came from Australian tender deliveries and prior-period US rebate adjustments[19]. Shingrix fell 17% in International markets[38], US volume declined with pricing keeping sales broadly stable, and the 12-month gain in the US immunization rate slowed to 3 percentage points from 4 points in the 2025 annual report[19][33].

The financial chain for vaccines starts with inclusion in government immunization programs and public tenders, which become publicly funded orders and pharmacy purchases and then Shingrix, Arexvy and meningitis vaccine shipments and sales[33][19]. Because vaccines carry higher margins than general medicines, the Shingrix ramp in Europe was one reason the core cost-of-sales ratio fell in the second quarter[9]. When US rebates accrued through Medicare Part D and other channels are adjusted, the change can retroactively affect quarterly revenue[18].

What remains unresolved is whether Shingrix can keep growing at double digits once the one-time catch-up from expanded European public funding ends. The third-quarter report should show whether vaccine sales are no worse than -5% at CER, whether Shingrix growth in Europe stays above 15%, how much the US Shingrix immunization rate gained over 12 months, and how Arexvy performs in the US fall stocking season. If third-quarter vaccine sales fall more than 5%, or Shingrix growth in Europe drops below 10%, the view that European growth can offset a US plateau would weaken.

Management says pressure on General Medicines should ease in the second half. Will the declines in Trelegy and US inhaled medicines narrow in the third quarter?

General medicines still account for nearly a third of turnover and more than 70% of supply volume and fund R&D and shareholder returns[21], so the size of their decline determines whether GSK can hold its full-year turnover guidance. In the second quarter general medicines fell 9% at CER[4] and US general medicines fell 17%[11]; in July GSK cut its full-year assumption to a mid-single-digit to low-single-digit decline[5]. After a 7% first-half decline, that assumption requires the second-half change to narrow to roughly -5% to +3%[4].

The evidence for easing comes from management's explanation and from overseas markets. Management said the second-quarter US decline reflected a high base from a one-off favorable pricing adjustment in the year-earlier quarter, said it saw pressure easing in the second half, and said the agreement with the US Centers for Medicare and Medicaid Services (CMS) brought no unexpected negative surprises[12]; Trelegy grew 9% in Europe and 12% in International markets[39]. The evidence against is that Trelegy's US sales fell 13% to £561 million[39], abandonment rates have stayed high across the whole triple-therapy inhaler class[12], and Transpire has filed paragraph IV patent challenges on two Trelegy strengths, with trial on the 100 mcg strength set for February 22, 2028[40].

General medicines feed into the financials through three paths. First, Medicare benefit design changes raise patient out-of-pocket costs, pushing up US abandonment and reducing prescriptions for inhalers such as Trelegy[41]; second, channel mix pricing adjustments and government rebates lower US net prices, and these adjustments cut Trelegy's second-quarter growth by 5 percentage points[31]; third, generic competition keeps eroding the share of older inhalers[31]. Because general medicines carry lower margins, their shrinkage further tilts the group mix toward specialty medicines and hurts turnover more than margin[9].

What remains unresolved is how large the underlying US decline is once the high base drops out, and how the Generous Model and state supplemental rebates will affect net prices. The Generous Model participation agreements signed by GSK and ViiV took effect on June 15, 2026, and supplemental rebate agreements with interested states were anticipated to be signed on or before October 1, 2026[37]. The third-quarter report should show whether general medicines do better than -6% at CER, whether Trelegy's US decline narrows and how fast US general medicines are shrinking. If general medicines fall more than 6%, or US general medicines fall more than 15%, the claim that pressure eases in the second half would be falsified.

Risks and Falsifiers

The first risk is the balance sheet: Nuvalent was funded mainly with debt, lifting net debt from £15.13 billion at the end of June to about £22 billion[15][29], while GSK also carries cash payments to Shionogi and a dividend of about 70 pence a year. The exposure sits in core EPS and free cash flow: acquisition interest has already moved core EPS guidance to the lower half of 7%-9%[6]; the contingent consideration owed to Shionogi was £5.43 billion at the end of 2025, with £1.19 billion expected to be paid within a year[14]; and the full-year 2026 dividend is expected to be 70 pence[30]. If third-quarter free cash flow stays near the second quarter's £1.99 billion[28], and GSK leaves its dividend expectation unchanged and reaffirms core EPS guidance, this concern would ease.

The second risk comes from US drug pricing policy and tariffs: Section 232 tariff relief depends on final implementation of the agreement with the US government, and the Generous Model and state supplemental rebates lower net prices on some products[37]. The US made up half of first-half 2026 turnover, £8.05 billion of £16.04 billion[4], and GSK's three US wholesalers bought a combined £13.35 billion in 2025[18]. If the supplemental rebate agreements are signed on schedule and GSK reaffirms in its third-quarter report that their impact is included in guidance, the current view holds; otherwise US net-price pressure has exceeded the guidance assumptions.

The third risk is intensifying competition in long-acting HIV combined with a fading US pricing benefit[29][13]. HIV is about 24% of turnover, and on 2025 sales of £7.69 billion, each percentage point of slower HIV growth costs about £77 million of annual revenue[17]; the Shionogi contingent consideration is also remeasured on sales forecasts and already produced a £392 million charge in the second quarter[27]. If third-quarter long-acting growth is at least 30% and HIV growth at CER is at least 9%, the worry about faster competitive erosion would not hold.

The fourth risk is that late-stage pipeline failures bring large impairments while faster R&D magnifies spending. In the second quarter, the failure of camlipixant's phase III program in chronic cough led to a £1.33 billion impairment and the termination of the Alector collaboration to a £371 million impairment, for a total of £1.90 billion[27], cutting reported operating profit 76% to £481 million[3]. On 2025 core R&D of £6.57 billion, each 10% increase in R&D adds about £660 million of annual cost[24]. If the third quarter brings no new major R&D impairment and the core operating margin is flat or higher year over year, this risk has not materialized.

The fifth risk is that the one-time catch-up from expanded European public funding ends while US penetration keeps slowing. Shingrix sales were £3.56 billion in 2025, about 39% of vaccine sales[17], and because vaccine margins are above the group average, the Shingrix ramp in Europe was one reason the core cost-of-sales ratio fell in the second quarter[9]. If third-quarter Shingrix growth in Europe is at least 15% and the 12-month gain in the US immunization rate holds at 3 percentage points[19], this risk has not yet appeared.

The sixth risk is that US inhaler net prices and volumes fall together as generics and patent challenges accelerate[39][40]. General medicines sales were £10.04 billion in 2025, so each extra percentage point of decline costs about £100 million of annual revenue[17]; the US rebate accrual was £4.89 billion at the end of 2025, estimate changes can retroactively affect quarterly revenue, and 2025 included £873 million of prior-period estimate changes[18]. If third-quarter general medicines are no worse than -2% at CER and the US decline narrows to within 8%, this concern would be falsified.

What to Watch Next

• Long-acting HIV switching: second-quarter HIV sales were £2.08 billion (+10%) and long-acting injectables £593 million (+34%), 35% of US HIV sales[8][35]. HIV growth of at least 4% with long-acting growth near 30% would confirm the view; HIV below 4% or long-acting below 20% would falsify it.
• Specialty growth versus investment: core operating profit was £2.80 billion (+7%, 33.3% margin), RI&I grew 19% and core R&D was £1.72 billion (+13%)[3][9]. Watch the first Nuvalent consolidation and the November 27 neladalkib decision. Positive core operating profit growth would confirm; a decline, or RI&I below 10%, would falsify.
• Vaccines holding flat: vaccines were £2.28 billion (+8%, including 3 points of rebate adjustments), Shingrix Europe grew 21% and the US immunization rate was 45%[19][38]. Vaccines no worse than -5% with Europe at least 15% would confirm; vaccines below -5% or Europe below 10% would falsify.
• General medicines decline narrowing: general medicines were £2.34 billion (-9%), US general medicines -17% and Trelegy US -13%[4][39]. Better than -6% would confirm; worse than -6%, or US worse than -15%, would falsify.
• Balance sheet: second-quarter free cash flow was £1.99 billion and post-deal net debt about £22 billion[28][29]. Sustained free cash flow with core EPS guidance and the 70 pence dividend intact would confirm; a new major impairment or a dividend change would weaken the view.

Conclusion

GSK's business is shaped by three forces: long-acting HIV injectables and respiratory and oncology launches drive double-digit specialty growth, higher-margin vaccines such as Shingrix support the mix, and general medicines keep shrinking under US pricing and generic pressure[4]. Second-quarter turnover was £8.41 billion and core operating profit £2.80 billion, up 5% and 7% at CER respectively[3]; but net debt reached about £22 billion after the Nuvalent deal[29], and core R&D grew 13%, faster than sales[9]. The central unresolved relationship is whether specialty and vaccine growth can outrun the combined drag of faster R&D, the Nuvalent consolidation and declining general medicines in the third quarter.

Third-party commentary since the second-quarter results does not yet amount to an independent business assessment. Between the July 28, 2026 results and October 2, the outside material available consisted mainly of brokers such as Jefferies, Berenberg and Citi changing their views on the shares, plus news recaps of deals and pipeline announcements; none of it offered independent analysis of GSK's operating drivers that could be cited. For that reason, no outside view is presented here, and those changes are not treated as a vote on the four core debates above.

What would actually change the picture is a combination of observations. If third-quarter HIV growth is at least 4%, long-acting injectables keep growing around 30%, core operating profit still grows after the Nuvalent consolidation and the general medicines decline narrows to better than -6%, the view that specialty growth can cover the investment needed ahead of patent expiry would strengthen. Conversely, if long-acting growth falls below 20%, core operating profit declines, vaccines fall more than 5% and free cash flow drops well below the second quarter's £1.99 billion[28], GSK would face weaker growth with a heavier debt load, and the current view would weaken materially.

Sources

[1] GSK 20-F filed 2026-03-06 · business description and product groups · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[2] Drillr earnings calendar (updated 2026-10-01) · GSK 2026-10-28 call · 2026-10-01 · Drillr earnings calendar

[3] GSK 6-K filed 2026-07-28 · Q2 2026 headline results · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[4] GSK 6-K filed 2026-07-28 · Q2 2026 turnover by product group · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[5] GSK 6-K filed 2026-07-28 · 2026 guidance · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[6] GSK Q2 2026 earnings call 2026-07-28 · guidance detail · 2026-07-28 · earnings-call · https://gateway.drillr.ai/mcp/private

[7] Drillr analyst_financial_estimates (updated 2026-10-01) · GSK quarter ending 2026-09-30 · 2026-10-01 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[8] GSK 6-K filed 2026-07-28 · Q2 2026 Specialty key drivers · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[9] GSK 6-K filed 2026-07-28 · Q2 2026 Core cost lines · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[10] GSK 6-K filed 2026-07-28 · Nuvalent acquisition (post balance sheet) · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[11] GSK 6-K filed 2026-09-08 · Q2 2026 regional drivers · 2026-09-08 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[12] GSK Q2 2026 earnings call 2026-07-28 · Q&A on General Medicines and long-acting HIV IP · 2026-07-28 · earnings-call · https://gateway.drillr.ai/mcp/private

[13] GSK 20-F filed 2026-03-06 · HIV growth drivers and ViiV ownership · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[14] GSK 20-F filed 2026-03-06 · contingent consideration liabilities · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[15] GSK 6-K filed 2026-07-28 · net debt at 30 June 2026 · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[16] GSK Q2 2026 earnings call 2026-07-28 · launches and Accelerate Growth programme · 2026-07-28 · earnings-call · https://gateway.drillr.ai/mcp/private

[17] GSK 20-F filed 2026-03-06 · FY2025 turnover by product group · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[18] GSK 20-F filed 2026-03-06 · US wholesalers and returns and rebates · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[19] GSK 6-K filed 2026-07-28 · Q2 2026 Vaccines key drivers · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[20] GSK 20-F filed 2026-03-06 · manufacturing network · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[21] GSK 20-F filed 2026-03-06 · General Medicines portfolio and Trelegy paragraph IV · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[22] GSK 20-F filed 2026-03-06 · FY2025 financial performance summary · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[23] GSK 20-F filed 2026-03-06 · FY2025 operating profit, cash and net debt · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[24] GSK 20-F filed 2026-03-06 · segment profit and R&D · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[25] GSK 20-F filed 2026-03-06 · 2025 dividends · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[26] GSK 6-K filed 2026-04-29 · Q1 2026 headline results · 2026-04-29 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[27] GSK 6-K filed 2026-07-28 · Q2 2026 impairments and remeasurements · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[28] GSK 6-K filed 2026-07-28 · Q2 2026 free cash flow · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[29] GSK Q2 2026 earnings call 2026-07-28 · stated risks · 2026-07-28 · earnings-call · https://gateway.drillr.ai/mcp/private

[30] GSK 6-K filed 2026-07-28 · outlooks and shareholder returns · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[31] GSK 6-K filed 2026-07-28 · Q2 2026 General Medicines key drivers · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[32] GSK 6-K filed 2026-07-28 · Q2 2026 cash generation and Shionogi payments · 2026-07-28 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[33] GSK 20-F filed 2026-03-06 · Shingrix 2025 performance · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[34] GSK 20-F filed 2026-03-06 · HIV patent expiry table · 2026-03-06 · 20-F · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=20-F&dateb=&owner=include&count=40

[35] GSK 6-K filed 2026-09-08 · Q2 2026 Specialty Medicines turnover by product · 2026-09-08 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[36] GSK 6-K filed 2026-04-29 · Q1 2026 Specialty and launch drivers · 2026-04-29 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[37] GSK 6-K filed 2026-09-08 · US pricing agreement and Accelerate Growth programme · 2026-09-08 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[38] GSK 6-K filed 2026-09-08 · Q2 2026 Vaccines turnover by region · 2026-09-08 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[39] GSK 6-K filed 2026-09-08 · Q2 2026 General Medicines turnover by region · 2026-09-08 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[40] GSK 6-K filed 2026-09-08 · Trelegy patent litigation · 2026-09-08 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40

[41] GSK 6-K filed 2026-04-29 · Q1 2026 Trelegy drivers · 2026-04-29 · 6-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131399&type=6-K&dateb=&owner=include&count=40